featured
Efficacy and Safety of the Novel Autotaxin Inhibitor Ziritaxestat in Patients With Idiopathic Pulmonary Fibrosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials
JAMA 2023 May 09;329(18)1567-1578, TM Maher, P Ford, KK Brown, U Costabel, V Cottin, SK Danoff, I Groenveld, E Helmer, RG Jenkins, J Milner, G Molenberghs, B Penninckx, MJ Randall, B Van Den Blink, A Fieuw, C Vandenrijn, S Rocak, I Seghers, L Shao, A Taneja, G Jentsch, TR Watkins, WA Wuyts, M Kreuter, N Verbruggen, N Prasad, MS WijsenbeekFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.